Although FCR was the first treatment regimen that prolonged OS in CLL patients, the OS of patients with del(17p) was not significantly different between both arms (HR 0.66; 95%CI 0.33-1.31), underscoring the poor response in the TP53 aberrant group. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.